Ancon is a UK-based MedTech company that has developed proprietary technologies for the detection of trace quantities of Volatile Organic Compounds (VOCs). It has a number of important applications in society including breath-based diagnostic testing for cancers, bacteria and viruses, including COVID-19 and significantly improved detection of explosives, narcotics and chemical threats. Ancon’s technology has the potential to provide faster diagnosis, point of care non-invasive detection, higher sensitivity and a more affordable alternative to current methods in detecting VOCs. Led by a highly experienced management and scientific team, Ancon is operating in a market that is unsaturated, large and continuing to grow, with opportunities for Ancon and partner that are scalable and attractive. Our Mission: To save lives and make a difference to society from the early, accurate and actionable detection of trace volatile organic compounds from a single, affordable test.